BeStock  
Stocks › Biotechnology › URGN

UroGen Pharma Ltd URGN

US equityMarket cap rank #2953Biotechnology
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

URGN at a glance

UroGen Pharma Ltd stock (URGN) sits at $27.65, down 12.86% today. The business is worth $1.36B in the market, good for #2953 of 3753 on our coverage list.

Over the past 52 weeks it has traded between $16.50 and $50.81, so it sits 45.6% below the top of that range. Holders are ahead 6.9% over twelve months, but down 40.1% across the last three months.

On the chart it has slipped under both the 50-day ($35.60) and 200-day ($31.92) moving averages; RSI is 40, and the last 30 sessions moved at roughly 90% annualized volatility.

Revenue for the quarter ended Sep 2026 was $89.00M, up 223.9% from a year earlier, and a net loss of $1.46M.

5 analysts follow the stock and the average call is "buy". The mean target, $62.20, sits 125.0% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$27.50 / $32.95
Average price today$29.63
Volume2.40MAvg (90d) 1.06M
Turnover$71.09M
Turnover rate5.51%of shares outstanding
Volume ratio1.13vs. recent average pace
Day amplitude13.65%
Market cap$1.36B
Float market cap$1.20B
Shares outstanding43.57M
EPS (TTM)-$3.19
P/B-10.83
Book value / share-$2.55
Net profit (TTM)-$156.46M
Net assets-$125.22M
30-day volatility89.8%annualized
Avg daily range (ATR)10.44%of price, 14 days
Max drawdown (1y)-50.8%-45.0% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

A
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

5 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 27.7 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation49.4
Growth—
Profitability14.5
Momentum33.2
Financial health16.6
Analyst view93.1

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$62.20+125.0% vs. current price
Consensus ratingBuy5 analysts covering
Morningstar fair value$28.54Close to fair value

Wall Street’s average 12-month target is $62.20, 125.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $28.54, so shares trade 3.1% below that estimate. On earnings multiple, it sits in the 4th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-12.9%
1 week
+5.6%
1 month
-21.3%
3 months
-40.1%
6 months
-4.3%
Year to date
+18.1%
1 year
+6.9%
Day range
$27.57$31.90
52-week range
$16.50$50.81

Technical signals

Full technicals →
Trend readLeaning bearish

2 bullish · 5 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-6.8%Bearish
Price vs 50-day average-22.3%Bearish
Price vs 200-day average-13.4%Bearish
50-day vs 200-day50d above 200dBullish
RSI (14)40.0Bearish
MACD (12,26,9)-2.03Bullish
Bollinger band position36%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How URGN ranks on BeStock

Market value#2941 of 3734
Closeness to 52-week high#2874 of 3724
Dollar volume today#1189 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

URGN is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on URGN.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on URGN

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

URGN stock: common questions

What is URGN's latest share price?

$27.65 is the latest print for URGN, a move of -12.86% against yesterday's close of $31.73. Today's low and high so far: $27.57 and $31.90.

How big is UroGen Pharma Ltd?

Equity value comes to $1.36B at the current price. By that measure it is number 2953 of the 3753 names in our coverage.

Where does URGN sit in its 52-week range?

The year's floor is $16.50 and the ceiling $50.81. Shares are 45.6% away from that ceiling.

Does URGN send cash back through a dividend?

Our data shows no dividend paid by UroGen Pharma Ltd over the trailing twelve months.

Do Wall Street analysts like URGN?

Of 5 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $62.20, with the most cautious at $56.00 and the most optimistic at $75.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on URGN.

Sign in to join the discussion.

Scroll to Top